Ahmad, T., Armuzzi, A., Bunce, M., Mulcahy-Hawes, K., Marshall, S.E., Orchard, T.R. et al. (2002) The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122: 854-866.
Allez, M., Lemann, M., Bonnet, J., Cattan, P., Jian, R. and Modigliani, R. (2002) Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 97: 947-953.
Beaugerie, L., Seksik, P., Nion-Larmurier, I., Gendre, J.P. and Cosnes, J. (2006) Predictors of Crohn's disease. Gastroenterology 130: 650-656.
Brant, S.R., Picco, M.F., Achkar, J.P., Bayless, T.M., Kane, S.V., Brzezinski, A. et al. (2003) Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis 9: 281-289.
Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R. et al. (2002) Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 8: 244-250.
Cosnes, J., Nion-Larmurier, I., Beaugerie, L., Afchain, P., Tiret, E. and Gendre, J.P. (2005) Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54: 237-241.
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H. et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660-667.
Dubinsky, M.C., Kugathasan, S., Mei, L., Picornell, Y., Nebel, J., Wrobel, I. et al. (2008) Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 6: 1105-1111.
Feagan, B.G., Bala, M., Yan, S., Olson, A. and Hanauer, S. (2005) Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 39: 390-395.
Feagan, B.G., Panaccione, R., Sandborn, W.J., D'Haens, G.R., Schreiber, S., Rutgeerts, P.J. et al. (2008) Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135: 1493-1499.
Hellers, G., Bergstrand, O., Ewerth, S. and Holmström, B. (1980) Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 21: 525-527.
Henckaerts, L. (2008) Genetic risk profiling and prediction of disease course in Crohn's disease patients. Acta Biomedica Lovaniensa 123-146.
Kandiel, A., Fraser, A.G., Korelitz, B.I., Brensinger, C. and Lewis, J.D. (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: 1121-1125.
Lichtenstein, G.R., Yan, S., Bala, M., Blank, M. and Sands, B.E. (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128: 862-869.
Loly, C., Belaiche, J. and Louis, E. (2008) Predictors of severe Crohn's disease. Scand J Gastroenterol 43: 948-954.
Longobardi, T., Jacobs, P., Wu, L. and Bernstein, C.N. (2003) Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol 98: 844-849.
Louis, E., Colard, A., Oger, A.F., Degroote, E., El Yafi, F. and Belaiche, J. (2001) Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49: 777-782.
Louis, E., Michel, V., Hugot, J.P., Reenaers, C., Fontaine, F., Delforge, M. et al. (2003) Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 52: 552-557.
Mekhjian, H.S., Switz, D.M., Watts, H.D., Deren, J.J., Katon, R.M. and Beman, F.M. (1979) National Cooperative Crohn's Disease Study: factors determining recurrence of Crohn's disease after surgery. Gastroenterology 77: 907-913.
Munkholm, P., Langholz, E., Davidsen, M. and Binder, V. (1995) Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30: 699-706.
Rieder, F., Schleder, S., Wolf, A., Dirmeier, A., Strauch, U., Obermeier, F. et al. (2008) Specific levels and combinations of the anti-glycan antibodies anti-L, anti-C, ALCA, ACCA, gASCA and AMCA contribute to diagnosis and differential diagnosis of patients with Crohn's disease and are associated with complicated disease and surgery. Gastroenterology 134: 392.
Seksik, P., Loftus, E., Beaugerie, L., Harmsen, W., Zinsmeister, A., Cosnes, J. et al. (2007) Validation of predictors of 5-year disabling CD in a population based cohort from Olmsted county, Minnesota, 1983-1996. Gastroenterology 132: A17, 80.
Siegel, C., Sadie, M., Marden, S., Persing, S.M., Larson, R.J. and Sands, B.E. (2008) Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis. Gastroenterology 134: A-144, 970.
Sonnenberg, A. (1989) Disability from inflammatory bowel disease among employees in West Germany. Gut 30: 367-370.
Toruner, M., Loftus, E., Harmsen, W., Zinsmeister, A.R., Orenstein, R., Sandborn, W.J. et al. (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134: 929-936.
Vernier-Massouille, G., Balde, M., Salleron, J., Turck, D., Dupas, J.L., Mouterde, O. et al. (2008) Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 135: 1106-1113.
Wolters, F.L., Russel, M.G., Sijbrandij, J., Ambergen, T., Odes, S., Rijs, L. et al. (2006) Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 55: 1124-1130.
Xavier, R.J. and Podolsky, D.K. (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
